Renaissance Technologies (RenTech)'s CTKB Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 676,700 shares of Cytek Biosciences, Inc. (CTKB) worth $2.96 M, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in CTKB, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 375,539 shares. Largest reduction occurred in Q2 2023, reducing 353,500 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Cytek Biosciences (CTKB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytek Biosciences (CTKB) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1,700 | Add 0.25% | 676,700 | $4.37 |
| Q4 2025 | -120,544 | Reduce 15.15% | 675,000 | $5.05 |
| Q3 2025 | -267,595 | Reduce 25.17% | 795,544 | $3.47 |
| Q2 2025 | +375,539 | Add 54.62% | 1.06 M | $3.40 |
| Q1 2025 | +225,000 | Add 48.64% | 687,600 | $4.01 |
| Q4 2024 | +251,000 | Add 118.62% | 462,600 | $6.49 |
| Q3 2024 | -22,300 | Reduce 9.53% | 211,600 | $5.54 |
| Q2 2024 | +233,900 | New Buy | 233,900 | $5.58 |
| Q4 2023 | -296,900 | Sold Out | 0 | $0.00 |
| Q3 2023 | +296,900 | New Buy | 296,900 | $5.52 |
| Q2 2023 | -353,500 | Sold Out | 0 | $0.00 |
| Q1 2023 | -38,300 | Reduce 9.78% | 353,500 | $0.01 |
| Q4 2022 | +179,900 | Add 84.90% | 391,800 | $0.01 |
| Q3 2022 | +49,000 | Add 30.08% | 211,900 | $14.72 |
| Q2 2022 | +108,600 | Add 200.00% | 162,900 | $10.73 |
| Q1 2022 | -54,700 | Reduce 50.18% | 54,300 | $10.77 |
| Q4 2021 | +109,000 | New Buy | 109,000 | $16.32 |
Renaissance Technologies (RenTech)'s Cytek Biosciences Investment FAQs
Renaissance Technologies (RenTech) first purchased Cytek Biosciences, Inc. (CTKB) in Q4 2021, acquiring 109,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Cytek Biosciences, Inc. (CTKB) for 17 quarters since Q4 2021.
Renaissance Technologies (RenTech)'s largest addition to Cytek Biosciences, Inc. (CTKB) was in Q2 2025, adding 1,063,139 shares worth $3.61 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 676,700 shares of Cytek Biosciences, Inc. (CTKB), valued at approximately $2.96 M.
As of the Q1 2026 filing, Cytek Biosciences, Inc. (CTKB) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Cytek Biosciences, Inc. (CTKB) was 1,063,139 shares, as reported at the end of Q2 2025.